Citius Pharmaceuticals Inc (CTXR) Given Average Recommendation of “Strong Buy” by Analysts

Shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Zacks has also given Citius Pharmaceuticals an industry rank of 73 out of 256 based on the ratings given to related companies.

Several equities research analysts have weighed in on the company. Zacks Investment Research downgraded Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 18th. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Citius Pharmaceuticals in a research note on Thursday, February 7th.

In other news, insider Myron Z. Holubiak purchased 129,450 shares of the stock in a transaction on Wednesday, April 3rd. The stock was bought at an average price of $1.55 per share, with a total value of $200,647.50. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 58.52% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in CTXR. Morgan Stanley acquired a new stake in Citius Pharmaceuticals during the 1st quarter valued at approximately $29,000. Renaissance Technologies LLC acquired a new stake in Citius Pharmaceuticals during the 3rd quarter valued at approximately $100,000. Finally, Baker Avenue Asset Management LP acquired a new stake in Citius Pharmaceuticals during the 1st quarter valued at approximately $120,000. 1.59% of the stock is owned by hedge funds and other institutional investors.

CTXR traded down $0.05 during trading on Friday, hitting $1.15. The stock had a trading volume of 81,448 shares, compared to its average volume of 189,097. Citius Pharmaceuticals has a twelve month low of $0.86 and a twelve month high of $3.15.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

Featured Story: Why is Cost of Capital Important?

Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with's FREE daily email newsletter.